Evgenia Filimianova

Evgenia Filimianova

Author
Evgenia Filimianova is a UK-based journalist covering a wide range of international stories, with a particular interest in foreign policy, economy, and UK politics.

LATEST

Europe’s Solar Surge Exposes Cracks in Aging Power Grid: Analysts

Europe’s Solar Surge Exposes Cracks in Aging Power Grid: Analysts

Israel Receives Remains of 2 More Hostages Returned by Hamas

Israel Receives Remains of 2 More Hostages Returned by Hamas

US, Russia Discussing Denuclearization, Trump Says

US, Russia Discussing Denuclearization, Trump Says

Trump Says Gaza Cease-Fire Intact Despite Israeli Strikes

Trump Says Gaza Cease-Fire Intact Despite Israeli Strikes

Netanyahu to Meet Security Chiefs After Israel Accuses Hamas of Cease-Fire Violation

Netanyahu to Meet Security Chiefs After Israel Accuses Hamas of Cease-Fire Violation

Turkey, UK Sign Multibillion-Dollar Deal for 20 Eurofighter Jets

Turkey, UK Sign Multibillion-Dollar Deal for 20 Eurofighter Jets

Novartis to Buy Avidity Biosciences for $12 Billion to Expand RNA-Based Drug Pipeline

Novartis to Buy Avidity Biosciences for $12 Billion to Expand RNA-Based Drug Pipeline

Europe’s Solar Surge Exposes Cracks in Aging Power Grid: Analysts

Europe’s Solar Surge Exposes Cracks in Aging Power Grid: Analysts

Israel Receives Remains of 2 More Hostages Returned by Hamas

Israel Receives Remains of 2 More Hostages Returned by Hamas

US, Russia Discussing Denuclearization, Trump Says

US, Russia Discussing Denuclearization, Trump Says

Trump Says Gaza Cease-Fire Intact Despite Israeli Strikes

Trump Says Gaza Cease-Fire Intact Despite Israeli Strikes

Netanyahu to Meet Security Chiefs After Israel Accuses Hamas of Cease-Fire Violation

Netanyahu to Meet Security Chiefs After Israel Accuses Hamas of Cease-Fire Violation

Turkey, UK Sign Multibillion-Dollar Deal for 20 Eurofighter Jets

Turkey, UK Sign Multibillion-Dollar Deal for 20 Eurofighter Jets

Novartis to Buy Avidity Biosciences for $12 Billion to Expand RNA-Based Drug Pipeline

Novartis to Buy Avidity Biosciences for $12 Billion to Expand RNA-Based Drug Pipeline